Human Data on Epigenetic Age Following Senolytic Treatment – Fight Aging!
A recent study on senolytic treatments in human patients revealed intriguing results regarding epigenetic age. Despite short-term increases in epigenetic age measured through immune cells in blood samples, the hoped-for lasting decrease was not observed. This raises questions about the sensitivity of current epigenetic clocks to the impact of senescent cells in aging. The study utilized dasatinib and quercetin, known for their senolytic effects in previous studies, yet the findings suggest potential limitations in addressing senescent cell burden in humans. The age range of participants may have also played a role, with some individuals potentially not having a significant burden of senescent cells due to their younger age. As research continues, exploring the effects of senolytic interventions like dasatinib, quercetin, and fisetin on DNA methylation clocks will shed more light on their potential impact on aging processes. Stay tuned for further updates on this intriguing topic!
